Form DEF 14A KURA ONCOLOGY For: 10 April

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, filed its definitive proxy statement (Form DEF 14A) with the U.S. Securities and Exchange Commission (SEC) on April 10, 2025, to provide shareholders with essential information ahead of its upcoming annual meeting. This mandatory regulatory filing outlines the matters to be voted on and details corporate governance procedures, enabling informed shareholder participation in corporate decision-making. The Form DEF 14A serves as the official notice for Kura Oncology's annual shareholder meeting, which is scheduled to occur later in 2025. The document typically includes the precise date, time, and location of the meeting, the agenda of proposals requiring a shareholder vote, and comprehensive background information on each item. Key proposals usually involve the election of the company's board of directors, ratification of the appointment of independent auditors, and advisory votes on executive compensation ("say-on-pay"). For a biotechnology firm like Kura Oncology, which is focused on developing precision medicines for cancer, these annual meetings and proxy materials are critical for maintaining investor confidence and transparent governance. The filing allows shareholders to review the company's leadership structure, director qualifications, and executive pay alignment with performance, especially as the company advances its clinical pipeline. The submission of this definitive proxy statement marks a routine but legally required step in the corporate calendar, ensuring the company adheres to federal securities regulations and facilitates the orderly conduct of its annual meeting.